- Home
- / Coya Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Coya Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$7.4
2024-10-29
Market Capitalization
$170.5 M
2024-10-29
Revenue
$7.9 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Revenue | 6.0M | 3.6M | 7.9M | |
| General and administrative expense | 4.8M | 7.8M | 8.9M | 11.4M |
| Operating expense total | 9.3M | 20.8M | 28.2M | |
| Depreciation and amortization | 27.4K | 27.4K | ||
| EBIT | (9.8M) | (7.9M) | (17.2M) | (22.6M) |
| EBIT margin, % | -485.4% | -283.9% | ||
| Pre tax profit | (7.3M) | (15.6M) | (21.2M) | |
| Income tax expense | 723.9K | (720.3K) | 3.1K | |
| Net Income | (12.2M) | (8.0M) | (14.9M) | (21.2M) |
| EPS | (4.7) | (1.0) | (1.3) |